It has strong antibacterial activity against Staphylococcus, Streptococcus, Pneumococcus, Peptostreptococcus, Neisseria gonorrhoeae, Branhamella catarrhalis, Escherichia coli, Klebsiella, Proteus (Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia anomala), Citrobacter, Enterobacter, and Haemophilus influenzae

Gatifloxacin belongs to the fourth generation of quinolone antibacterial drugs. It is a racemic compound of 8-methoxyfluoroquinolone. It has a broad spectrum of activity against Gram-negative and Gram-positive microorganisms in vitro. Its R- and S-enantiomers have the same antibacterial activity. The antibacterial effect is achieved by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes.

This product is a semi-synthetic penicillin that is acid-resistant and penicillinase-resistant. It has antibacterial activity against Gram-positive cocci and Neisseria. Its antibacterial activity against enzyme-producing strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococci) is stronger than that of oxacillin, but its antibacterial effect against penicillin-sensitive Staphylococci and various streptococci is weaker than that of penicillin, and it is ineffective against methicillin-resistant Staphylococci.

Rifaximin is a broad-spectrum intestinal antibiotic that inhibits bacterial RNA synthesis by irreversibly binding to the β-subunit of bacterial DNA-dependent RNA polymerase, and ultimately inhibits bacterial protein synthesis. It has a bactericidal effect on most Gram-positive and Gram-negative bacteria, including aerobic and anaerobic infections. Since rifaximin is not absorbed by the intestine when taken orally, it exerts its antibacterial effect locally by killing intestinal pathogens.

This product is a whole gastrointestinal tract motility drug, which can enhance esophageal peristalsis and lower esophageal sphincter tension, prevent gastric contents from reflux into the esophagus, and improve esophageal clearance; increase gastric and duodenal contractility and coordination of gastric antrum and duodenum; reduce duodenal and gastric reflux, improve gastric and duodenal emptying; strengthen intestinal movement and promote small and large intestine transit. This product does not increase the basal and pentagastrin-induced gastric acid secretion. In addition, it has almost no effect on plasma prolactin levels.